Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer

  • Chapter
Colorectal Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 813 Accesses

Abstract

Given the number of active drugs and combinations available, the choice of second-line therapy in metastatic colorectal cancer can be complicated. It is influenced by many factors, such as the nature of the first-line therapy, the potential toxicity of one regimen vs another, and the overall goal of treatment for the patient. In this chapter, we focus our discussion on the therapeutic strategies that can be used in the treatment of colorectal cancer after the failure of first-line therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Grothey A, Sargent D, Goldberg R, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–1214.

    Article  PubMed  CAS  Google Scholar 

  2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  3. Douillard J-Y, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  4. De Gramont A, Figer A, Homerin M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.

    PubMed  Google Scholar 

  5. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–147.

    PubMed  CAS  Google Scholar 

  6. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21: Abstract 512.

    Google Scholar 

  7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–345.

    Article  PubMed  CAS  Google Scholar 

  9. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–237.

    Article  PubMed  CAS  Google Scholar 

  10. Hedrick E, Hurwitz H, Sarkar S, et al. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 2004;22(14S): Abstract 3517.

    Google Scholar 

  11. Presta IG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–4599.

    PubMed  CAS  Google Scholar 

  12. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at the Am Soc Clin Oncol Annual Meeting 2005 (Abstract 2).

    Google Scholar 

  13. Goldberg R, Kirkpatrick P. Cetuximab. Nature Rev Drug Discov 2005;4:S10–S11.

    Article  Google Scholar 

  14. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracilleucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;11:2059–2069.

    Article  Google Scholar 

  15. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/ bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at Am Soc Clin Oncol Annual Meeting 2005 (Abstract 3508).

    Google Scholar 

  16. Rougier P, Van Custem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–1412.

    Article  PubMed  CAS  Google Scholar 

  17. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–1418.

    Article  PubMed  CAS  Google Scholar 

  18. Maughan T, on behalf of the NCRI colorectal group. Fluorouracil (FU), oxaliplatin (Ox), CPT-11 (irinotecan, Ir), use and sequencing, in advanced colorectal cancer (ACRC): the UK MRC FOCUS (CR08) Trial. Presented at Am Soc Clin Oncol Annual Meeting, 2005 (Abstract 165).

    Google Scholar 

  19. Fong Y, Cohen A, Fortner J, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938–946.

    PubMed  CAS  Google Scholar 

  20. Adam R, Delvart V, Pascal G, et al. Resection of non resectable liver metastases after chemotherapy: prognostic factors and long term results. Proc Am Soc Clin Oncol 2004; 22(14S):Abstract 3550.

    Google Scholar 

  21. Alberts SR, Donohue JH, Mahoney MR, et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment group (NCCTG) phase II study. Proc Am Soc Clin Oncol 2003;22:Abstract 1053.

    Google Scholar 

  22. Fernando N, Yu D, Morse M, et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. Am Soc Clin Oncol Annual Meeting 2005 (Abstract 3556).

    Google Scholar 

  23. Saltz L. Metastatic colorectal cancer: is there one standard approach? Oncology 2005; 19:1147–1149.

    PubMed  Google Scholar 

  24. Tukey R, Strassburg C, Mackenzie P. Pharmacogenomics of human UDP-glucoronosyltransferases and irinotecan toxicity. Mol Pharmacol 2002;62:446–450.

    Article  PubMed  CAS  Google Scholar 

  25. Lenz HJ. Pharmacogenomics in colorectal cancer. Semin Oncol 2003;30:47–53.

    Article  PubMed  CAS  Google Scholar 

  26. Allen W, Johnston P. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005;23:4545–4552.

    Article  PubMed  CAS  Google Scholar 

  27. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidilate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309–316.

    PubMed  CAS  Google Scholar 

  28. Shirota Y, Stoelmacher J, Brabender J, et al. ERCC1 and thymidilate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298–4304.

    Google Scholar 

  29. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344–354.

    PubMed  CAS  Google Scholar 

  30. Grothey A, McLeod HL, Green EM, et al. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. American Society of Clinical Oncology Annual Meeting 2005, Abstract 3509.

    Google Scholar 

  31. McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (CRC): results from an intergroup trial. Proc Am Soc Clin Oncol 2003;22:Abstract 1013.

    Google Scholar 

  32. Innocenti F, Undevia SD, Rosner GL, et al. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes. Am Soc Clin Oncol Annual Meeting 2005, Abstract 2006.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angele, CA

    Anthony B. El-Khoueiry MD

  2. Department of Gastrointestinal Oncology, University of Southern California/Kenneth Norris Comprehensive Cancer Center, Los Angeles, CA

    Heinz-Josef Lenz MD

Authors
  1. Anthony B. El-Khoueiry MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heinz-Josef Lenz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

    Leonard B. Saltz MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

El-Khoueiry, A.B., Lenz, HJ. (2007). Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer. In: Markman, M., Saltz, L.B. (eds) Colorectal Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-215-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-215-1_7

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-751-8

  • Online ISBN: 978-1-59745-215-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation